Dr. Kankeu Fonkoua is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511
Summary
- Gastrointestinal Oncologist with focus on Hepatobiliary Cancers.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2018 - 2021
Penn State Milton S Hershey Medical CenterResidency, Internal Medicine, 2015 - 2018
Pennsylvania State University College of MedicineClass of 2015
Certifications & Licensure
MN State Medical License 2018 - 2025
PA State Medical License 2015 - 2018- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Young Investigator Award American Society of Clinical Oncology (ASCO), 2020
- Outstanding Hematology/Oncology Fellow Award Minnesota Society of Clinical Oncology (MSCO), 2020
Clinical Trials
- Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations Start of enrollment: 2021 Jan 11
Roles: Contact
- Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma Start of enrollment: 2021 Dec 07
Roles: Contact
Publications & Presentations
PubMed
- Participant Evaluation of a Multi-disciplinary Oncology Preceptorship Training Program for Oncology Health Professionals from Kumasi, Ghana.Kenneth W Merrell, Thomas Okpoti Konney, Osei Acheamfour, Joseph Lucido, Abena Yeboah Aduse-Poku
Journal of Cancer Education. 2024-08-01 - 7 citationsCD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.R Leo Sakemura, Claudia Manriquez Roman, Paulina Horvei, Elizabeth L Siegler, James H Girsch
Blood. 2024-01-18 - Immunohistochemical basis for FAP as a candidate theranostic target across a broad range of cholangiocarcinoma subtypes.Laura C Jorgenson, Michael S Torbenson, Thorvardur R Halfdanarson, Lionel A Kankeu Fonkoua, Nguyen H Tran
Frontiers in Nuclear Medicine. 2024-01-01
Journal Articles
- The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other MalignanciesJill P Smith, Lionel Kankeu Fonkoua, Terry W Moody, International journal of biological sciences, 3/2016
- Immunotherapy in Gastric Carcinoma: Current Status and Future PerspectivesLionel Kankeu Fonkoua, Nelson S Yee, Clinical Cancer Drugs, 10/2015
Abstracts/Posters
- Enhanced efficacy of anti-VEGFR2/taxane therapy after progression on immune checkpoint inhibition (ICI) in patients (pts) with metastatic gastroesophageal adenocarcino...Lionel Aurelien Kankeu Fonkoua, Sakti Chakrabarti, Mohamad Bassam Sonbol, Pashtoon Murtaza Kasi, Jason Scott Starr, Alex J Liu, Melanie C. Bois, Henry C. Pitot, Helen ..., Journal of Clinical Oncology/ASCO GI Cancer Symposium, San Francisco, 2/4/2020
- Molecular profiling-guided therapy in gastroesophageal carcinoma: A single-institution experience.Lionel Aurelien Kankeu Fonkoua, Jason Liao, and Nelson S. Yee, Journal of Clinical Oncology/American Society of Clinical Oncology (ASCO), 6/2017
- The Use of Cationic Nanoliposomes Laden with siRNAs to Gastrin As a Target for Pancreatic CancerJill P. Smith, Craig W. Fenn, Gail L. Matters, Christopher O. McGovern, Lionel A. Kankeu Fonkoua, Calpurnia Jayakumar, Sriram Shanmugavelandy, James Kaiser, Mark Kester, Gastroenterology, 5/2009
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
